8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs

8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs

Neuromuscular blocking drugs (NMBDs) interrupt neurotransmission at the skeletal motor endplate. They are classified into depolarizing agents (suxamethonium) and non-depolarizing agents (benzylisoquinoliniums and aminosteroids). Mastery of their receptor interactions, degradation kinetics, active metabolites, and clinical toxicity profiles is fundamental to modern anaesthesia.

---

1. Neuromuscular Junction Physiology and Receptor Architecture

Skeletal muscle contraction requires sequential electrical, chemical, and electrochemical signaling across the neuromuscular junction (NMJ).

                         [ PRESYNAPTIC MOTOR NERVE TERMINAL ]
                                      |
                     Action Potential Depolarization
                                      |
                     Voltage-gated P/Q-type $Ca^{2+}$ Channels Open
                                      |
                       $Ca^{2+}$ Influx Triggers SNARE Fusion
                                      |
                     ACh Released into Synaptic Cleft (50 nm)
                                      |
        +-----------------------------+-----------------------------+
        |                                                           |
        v                                                           v
  [ POSTSYNAPTIC MEMBRANE ]                                [ SYNAPTIC CLEFT ]
  Two ACh molecules bind two $\alpha_1$ subunits            Acetylcholinesterase
  Heteropentamer: $(\alpha_1)_2 \beta_1 \delta \epsilon$      Hydrolyzes ACh in <1 ms
  Central ionophore opens $\rightarrow$ $Na^+/Ca^{2+}$ enter     into choline & acetate
  Endplate Potential (EPP) propagates along sarcolemma

The Postsynaptic Nicotinic Acetylcholine Receptor ($nAChR$)

The postsynaptic $nAChR$ is a member of the Cys-loop ligand-gated ion channel superfamily. It consists of five glycoprotein subunits arranged circumferentially around a central water-filled ion conducting pore:

• Adult Junctional Receptor: Heteropentamer composed of two $\alpha_1$, one $\beta_1$, one $\delta$, and one $\epsilon$ subunit [$(\alpha_1)_2 \beta_1 \delta \epsilon$]. Channel opening requires the simultaneous binding of two acetylcholine molecules to the two $\alpha_1$ subunits (at the $\alpha-\delta$ and $\alpha-\epsilon$ interfaces). This induces a conformational rotation that opens the channel for ~1 millisecond, conducting an inward flow of $Na^+$ and $Ca^{2+}$ and an outward flow of $K^+$.
• Fetal / Immature Extrajunctional Receptors: Synthesized in developing fetal muscle and re-expressed following motor denervation, thermal burn injury, or prolonged immobilization. They consist of an embryonic heteropentamer where the $\epsilon$ subunit is replaced by a $\gamma$ subunit [$(\alpha_1)_2 \beta_1 \delta \gamma$] or a homopentamer of $\alpha_7$ subunits.

Characteristics of Extrajunctional Receptors

1. Distribution: Spread across the entire muscle sarcolemma beyond the confines of the motor endplate.
2. Conductance and Kinetics: Extrajunctional receptors have lower single-channel conductance but a 2- to 10-fold longer mean channel open time than mature adult receptors.
3. Pharmacological Sensitivity: Exquisitely sensitive to depolarizing drugs (suxamethonium) and relatively resistant to non-depolarizing agents.
4. Hyperkalemic Vulnerability: When exposed to suxamethonium, widespread opening of extrajunctional receptors along the entire length of the muscle fiber causes massive, uncontrolled potassium efflux into the circulation.

---

2. Suxamethonium (Succinylcholine)

Suxamethonium is the only depolarizing neuromuscular blocking agent in clinical use. It consists chemically of two acetylcholine molecules joined back-to-back through their acetate methyl groups.

        (CH_3)_3N^+ - CH_2 - CH_2 - O - CO - CH_2 - CH_2 - CO - O - CH_2 - CH_2 - N^+(CH_3)_3
                                 [ Suxamethonium Molecule ]

Mechanism of Action: The Depolarizing Blockade

Suxamethonium binds to both $\alpha_1$ subunits of the $nAChR$ and acts as a receptor agonist. It triggers channel opening and widespread endplate depolarization. Because junctional acetylcholinesterase cannot metabolize suxamethonium, the drug remains bound to the receptor, maintaining persistent postjunctional depolarization.

This continuous depolarization leads to voltage-dependent inactivation of perijunctional voltage-gated $Na^+$ channels (their inactivation $h$-gates close). Consequently, the perijunctional membrane cannot generate or propagate action potentials, producing complete flaccid skeletal muscle paralysis.

Phase I vs Phase II Block

Neuromuscular blockade produced by suxamethonium exhibits two distinct physiological phases:

Metabolism and Butyrylcholinesterase Variants

Suxamethonium is metabolized in the plasma and liver by butyrylcholinesterase (pseudocholinesterase / plasma cholinesterase, coded by the $BCHE$ gene on chromosome 3). Suxamethonium is cleaved into succinylmonocholine (possessing 1/20th to 1/50th neuromuscular blocking potency) and then slowly into succinic acid and choline. Less than 10% of the administered dose reaches the neuromuscular junction.

The Dibucaine Number Test

Dibucaine is an amide local anaesthetic that selectively inhibits normal, wild-type pseudocholinesterase by approximately 80%, but inhibits atypical pseudocholinesterase by only 20%. The Dibucaine Number is defined as the percentage of pseudocholinesterase enzymatic activity inhibited by dibucaine under standardized laboratory conditions. It evaluates the qualitative genetic function (phenotype) of the enzyme, NOT the quantitative circulating level.

Dibucaine Number = [ 1 - (Enzyme Activity with Dibucaine / Enzyme Activity without Dibucaine) ] x 100

Clinical Trap: When managing prolonged apnea following suxamethonium in a homozygous atypical patient, do not administer neostigmine. Neostigmine inhibits any residual pseudocholinesterase activity, further prolonging the block. Management consists of continued mechanical ventilation, sedation, and patience until spontaneous recovery occurs.

Adverse Effects of Suxamethonium

1. Lethal Hyperkalemia: In healthy individuals, suxamethonium increases serum potassium by $0.5\text{ mEq/L}$ ($0.5\text{ mmol/L}$). In conditions with upregulated extrajunctional receptors, suxamethonium precipitates massive potassium efflux, raising serum potassium to $>8-10\text{ mmol/L}$ and triggering immediate refractory ventricular fibrillation or asystolic arrest. Contraindicated in:
   • Severe thermal burns (vulnerable from 24-48 hours post-injury up to 1-2 years).
   • Massive denervation injury (spinal cord transection, ischemic stroke, peripheral nerve injury after 48-72 hours).
   • Prolonged intensive care immobility and severe abdominal sepsis.
   • Muscular dystrophies (e.g., Duchenne, Becker muscular dystrophy).
   • Severe motor neuropathies (e.g., Guillain-Barré syndrome, ALS).
2. Cardiac Dysrhythmias and Bradycardia: Stimulates muscarinic $M_2$ receptors in the sinoatrial node, provoking severe sinus bradycardia, nodal escape rhythms, or sinus arrest. Most pronounced following a second dose administered within 5 minutes, or after a single dose in pediatric patients. Prevented by prior administration of intravenous atropine.
3. Elevated Compartment Pressures:
   • Intraocular Pressure (IOP): Increases by 5 to 10 mmHg for 5 to 10 minutes due to prolonged tonic contracture of extraocular rectus muscles and choroidal venous engorgement. Contraindicated in open-globe injuries.
   • Intragastric Pressure: Increases by 15 to 20 $\text{cmH}_2\text{O}$ due to abdominal wall fasciculations. However, lower esophageal sphincter (LES) barrier tone rises simultaneously, preserving the gastroesophageal pressure gradient in patients with intact sphincters.
   • Intracranial Pressure (ICP): Transient increase mediated by muscle spindle afferent stimulation; attenuated by a defasciculating dose of a non-depolarizing agent.
4. Postoperative Muscle Myalgia: Occurs in 20% to 50% of patients, particularly young ambulatory women. Caused by shearing micro-trauma during uncoordinated fasciculations. Attenuated by pretreatment with NSAIDs or a defasciculating dose (10% of $ED_{95}$) of a non-depolarizing blocker.
5. Malignant Hyperthermia (MH) Trigger: Potent trigger in patients with mutations in the skeletal ryanodine receptor ($RYR1$) or voltage-gated calcium channel ($CACNA1S$) genes. Isolated masseter muscle spasm (MMS) following suxamethonium indicates high probability of MH susceptibility.

---

3. Non-Depolarizing Neuromuscular Blockers: General Principles

Non-depolarizing NMBDs act as competitive antagonists at the postjunctional $nAChR$. They bind to one or both $\alpha_1$ subunits without inducing a conformational change, sterically obstructing endogenous acetylcholine from binding.

   Single twitch height depressed: >75% of receptors blocked
   Train-of-Four count disappears (0 twitches): >90-95% of receptors blocked
   Surgical relaxation achieved: 85-95% receptor block

Hallmarks of Non-Depolarizing Blockade

• Fade on Train-of-Four (TOF): Progressive reduction in the height of successive twitches ($T_4 < T_3 < T_2 < T_1$). Fade results from competitive antagonism of presynaptic nicotinic receptors, which normally facilitate the mobilization and vesicular release of acetylcholine during high-frequency repetitive nerve stimulation.
• Tetanic Fade: Inability to sustain muscle contraction during 50 Hz or 100 Hz stimulation.
• Post-Tetanic Facilitation: Enhanced twitch response following a tetanic train due to transient accumulation of presynaptic $Ca^{2+}$.
• Reversibility: Fully antagonized by acetylcholinesterase inhibitors (neostigmine) or selective encapsulating agents (sugammadex).

---

4. Benzylisoquinolinium Compounds

Benzylisoquinoliniums are characterized by absence of steroidal rings and clearance mechanisms that are predominantly independent of renal or hepatic function.

                             [ BENZYLISOQUINOLINIUMS ]
                                         |
        +--------------------------------+--------------------------------+
        |                                                                 |
   [ ATRACURIUM ]                                                 [ CISATRACURIUM ]
   - Mixture of 10 stereoisomers                                  - Single purified 1R-cis 1'R-cis isomer
   - Hofmann elimination (~1/3)                                   - Hofmann elimination (77%)
   - Non-specific ester hydrolysis (~2/3)                         - Minimal laudanosine (5-10x less)
   - Generates laudanosine (epileptogenic)                         - 3 to 4 times more potent ($ED_{95} = 0.05$ mg/kg)
   - Histamine release at high doses                              - ZERO histamine release

Atracurium

• Metabolism: Cleared through two distinct organ-independent pathways:
  1. Hofmann Elimination (~33%): A purely chemical, non-enzymatic spontaneous molecular degradation that occurs at physiological body temperature ($37^\circ\text{C}$) and pH (7.40). The rate of Hofmann elimination accelerates with alkalosis and hyperthermia, and decelerates with acidosis and hypothermia.
  2. Non-specific Ester Hydrolysis (~67%): Enzymatic cleavage by ubiquitous plasma and tissue carboxylesterases (distinct from pseudocholinesterase).
• Laudanosine Toxicity: Both degradation pathways generate laudanosine, a tertiary amine metabolite. Laudanosine readily crosses the blood-brain barrier and can induce central nervous system excitation, lowered seizure thresholds, and epileptogenic activity during prolonged high-dose infusions in the ICU, particularly in patients with concurrent renal failure (as laudanosine is eliminated by the kidneys).
• Histamine Release: Rapid bolus administration stimulates mast cell degranulation, causing transient arterial hypotension, reflex tachycardia, cutaneous facial erythema, and bronchospasm.

Cisatracurium

• Pharmacology: The purified $1R\text{-cis } 1'R\text{-cis}$ stereoisomer of atracurium. It is 3 to 4 times more potent than atracurium ($ED_{95} \approx 0.05\text{ mg/kg}$ vs $0.2\text{ mg/kg}$).
• Elimination: Cleared primarily by Hofmann elimination (77%) and renal excretion (16%). Non-specific ester hydrolysis plays a negligible role.
• Clinical Superiority: Because of its higher potency, a substantially lower mass of drug is administered, generating 5- to 10-fold less laudanosine than atracurium. Crucially, cisatracurium causes zero histamine release even at 8 times its $ED_{95}$, avoiding hemodynamic instability. It is the agent of choice in end-stage renal and hepatic failure.

Mivacurium

• Pharmacology: Short-acting benzylisoquinolinium ($ED_{95} \approx 0.07\text{ mg/kg}$, duration 15-20 min).
• Metabolism: Rapidly hydrolyzed by plasma butyrylcholinesterase (pseudocholinesterase) at 70% to 88% the rate of suxamethonium. Prolonged neuromuscular blockade occurs in patients with atypical pseudocholinesterase (homozygous atypical patients experience 4 to 8 hours of paralysis).
• Adverse Effects: Rapid boluses provoke substantial histamine release and transient hypotension.

---

5. Aminosteroid Compounds

Aminosteroids feature a steroid nucleus with attached quaternary ammonium groups. They do not trigger histamine release and are amenable to selective encapsulation by sugammadex.

                                [ AMINOSTEROIDS ]
                                        |
        +-------------------------------+-------------------------------+
        |                               |                               |
   [ ROCURONIUM ]                 [ VECURONIUM ]                 [ PANCURONIUM ]
   - Low potency ($ED_{95} = 0.3$)    - Intermediate duration        - Long duration (60-120 min)
   - Rapid onset (60-90 s at 1.2) - Hepatic deacetylation        - Renal excretion (60-80%)
   - Hepatic uptake & biliary (70%) - Active 3-OH metabolite       - Vagolytic tachycardia
   - Reversed by sugammadex        - Accumulates in renal failure  - Inhibits cardiac $M_2$

Rocuronium

• Rapid Onset Principle: Rocuronium has a lower potency ($ED_{95} \approx 0.3\text{ mg/kg}$) compared to vecuronium or pancuronium. Counterintuitively, lower potency produces faster onset of action: a lower potency requires administering a larger molar quantity of molecules to occupy the necessary receptor fraction (e.g., $1.2\text{ mg/kg} = 4 \times ED_{95}$ for RSI). This delivers a massive concentration gradient between the intravascular compartment and the neuromuscular biophase, driving rapid diffusion across the junctional cleft. At 1.2 mg/kg, excellent intubating conditions are achieved in 60 to 90 seconds, establishing rocuronium as the primary non-depolarizing alternative to suxamethonium for Rapid Sequence Induction.
• Elimination: Cleared primarily unchanged via hepatic uptake and biliary excretion (~70%), with renal excretion accounting for 10% to 30%. It has no active metabolites. Duration of action is prolonged in liver cirrhosis and advanced age.
• Cardiovascular Profile: Hemodynamically inert at clinical doses; no histamine release.

Vecuronium

• Pharmacology: Intermediate-acting aminosteroid with high potency ($ED_{95} \approx 0.05\text{ mg/kg}$) and a slower onset of 2.5 to 3 minutes.
• Metabolism and Active Metabolite: Undergoes hepatic deacetylation into three metabolites: 3-hydroxy, 17-hydroxy, and 3,17-dihydroxyvecuronium. The 3-hydroxyvecuronium metabolite possesses ~50% of the neuromuscular blocking potency of the parent drug and is eliminated exclusively by the kidneys. In renal impairment or following prolonged ICU infusions, 3-hydroxyvecuronium accumulates, precipitating prolonged paralysis.
• Cardiovascular Stability: Devoid of autonomic side effects; does not cause histamine release.

Pancuronium

• Pharmacology: Long-acting bisquaternary aminosteroid ($ED_{95} \approx 0.07\text{ mg/kg}$, duration 60-120 min).
• Elimination: Predominantly cleared by renal excretion (60-80%).
• Vagolytic Tachycardia: Pancuronium uniquely causes hypertension and tachycardia by competitively blocking cardiac muscarinic $M_2$ receptors (vagolytic effect) and inhibiting sympathetic neuronal reuptake of norepinephrine.

---

6. Comprehensive Comparison Table of Neuromuscular Blockers